Jazz Pharmaceuticals reported a record second-quarter 2026 revenue of $1.2 billion, marking its highest quarterly total and double-digit growth across all major brands. The company’s Chief Commercial Officer, Samantha Pearce, highlighted the momentum across its pipeline, emphasizing rare-disease therapies as a key driver of expansion. Recent acquisitions—including Saniona, Chimerix, and AbCellera—have bolstered its capabilities in oncology and neurology, while ongoing development efforts aim to address underserved patient populations, such as idiopathic hypersomnia and KCNT1 epilepsy.
ZYHERA, Jazz’s PD-1 inhibitor for metastatic breast cancer, saw its sales guidance lifted to a range of $3 billion to $5 billion, reflecting confidence in its clinical data and potential. Top-line results from a Phase III study are expected in the second half of 2027 to early 2028. Meanwhile, Zepzelca, approved for first-line maintenance in biliary tract cancer, generated over $100 million in Q2, with 30% to 40% of its revenue coming from this segment. Xywav, the only FDA-approved treatment for idiopathic hypersomnia, added 525 net patients in the quarter, with two-thirds of new additions stemming from the condition.
Epidiolex, Jazz’s CBD-based epilepsy medication, achieved 16% revenue growth and 14% volume growth globally. The company is also advancing Phase III studies for epileptic encephalopathies and juvenile myoclonic epilepsy, targeting populations of 120,000 to 150,000 and 60,000 U.S. patients, respectively. In a separate development, Actio Pharmaceuticals’ ABS-1230 for KCNT1 epilepsy is expected to launch within one to two years, pending deal closure.
Jazz’s stock performance has mirrored its growth, up 42% year-to-date and 90% over the prior year, with a P/E ratio of 16.4 and a beta of 0.36. The company’s prescriber overlap in biliary tract cancer remains robust at 90%, aligning with its standard-of-care market share of over 50%. Pearce underscored the company’s strategy of prioritizing rare diseases, noting that while it has expanded into oncology and neurology through acquisitions, it remains open to exploring new areas—provided they meet proof-of-concept milestones.
At the Citigroup Biopharma Back to School Summit 2026, Jazz highlighted its corporate development pipeline, which includes strategic investments in biotech and pharmaceutical innovation. The focus on rare diseases reflects both market demand and regulatory tailwinds, as therapies targeting niche patient groups often face fewer competitors and higher margins.
